SAB Biotherapeutics Reports Third Quarter 2021 Financial Results and Provides Company Update
November 22, 2021 07:00 ET
|
Sab Biotherapeutics, Inc.
Advanced SAB-185 to Phase 3 in NIH-Sponsored ACTIV-2 Trial for treatment of COVID-19 following positive DSMB recommendation at interim analysis Awarded additional $60.5 million from DoD in expanded...
SAB Biotherapeutics Debuts as Publicly Traded Next-Generation Immunotherapy Company
October 25, 2021 07:40 ET
|
Sab Biotherapeutics, Inc.
Completed Business Combination with Big Cypress Acquisition Corp. Common stock to commence trading on the Nasdaq Global Market October 25, 2021, under the ticker symbol “SABS” SIOUX FALLS, S.D.,...